Skip to main
  1. Stocks
  2. TriSalus Life Sciences Inc
  3. Forecast
TLSI

TLSI Stock Forecast & Price Target

TLSI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TriSalus Life Sciences is well positioned because its TriNav PEDD platform addresses a real clinical and economic gap: it improves selective delivery in a market where roughly 90% of liver embolization procedures still rely on standard catheters, while 2026 evidence showed better tumor targeting, higher response rates, and about $7,700 of avoided billed charges per patient. The reimbursement backdrop is also improving, with permanent HCPCS codes and, effective January 1, 2027, higher Medicare payment rates and an office-based lab payment that should strengthen provider economics and expand access, supporting adoption from a current roughly 10% liver share. Growth optionality is substantial, since TriNav Advance broadens access to smaller vessels and adjacent indications could expand the company’s addressable market from roughly $480M in liver to nearly $2.5B, while 2025 revenue of $45.2M and FY26 guidance of $54M-$57M show an already scaling commercial base.

Bears say

TriSalus Life Sciences is facing a weaker-than-expected commercial ramp as 3Q26 revenue of $12.9M missed consensus and forced FY26 guidance down to $46M-$48M from $54M-$57M, reflecting slower productivity in expansion territories and a delayed benefit from TriNav Advance. The business remains highly concentrated in TriNav, so adoption risk, annual reimbursement resets, and ongoing 510(k) regulatory uncertainty create a fragile revenue base, while the evidence for PEDD is still largely retrospective and single-center. With cash of $41.1M against $32.4M of long-term debt and a net loss of $0.15 per diluted share in 3Q26, the company may need additional capital in mid-2027, leaving dilution risk an important overhang.

TLSI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TriSalus Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

TLSI Analyst Forecast & Price Prediction

Get the latest TLSI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TLSI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TriSalus Life Sciences Inc (TLSI) Forecast

Analysts have given TLSI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TLSI has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TriSalus Life Sciences Inc (TLSI)


TLSI Analyst Forecast & Price Prediction

Get the latest TLSI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TLSI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TLSI stock data and trends